Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
2(40%)
Results Posted
100%(1 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
4
80%
Ph early_phase_1
1
20%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
4(80.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Active, not recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
33.3%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (20.0%)
Phase 14 (80.0%)

Trials by Status

completed120%
terminated240%
active_not_recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
terminatedphase_1

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

NCT03334305
active_not_recruitingphase_1

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT06254326
active_not_recruitingphase_1

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
terminatedphase_1

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

NCT03396575
completedearly_phase_1

Entolimod, an Adjuvant for Vaccine Augmentation

NCT03063736

Clinical Trials (5)

Showing 5 of 5 trials
NCT03334305Phase 1

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

Terminated
NCT06254326Phase 1

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Active Not Recruiting
NCT06514898Phase 1

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Active Not Recruiting
NCT03396575Phase 1

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Terminated
NCT03063736Early Phase 1

Entolimod, an Adjuvant for Vaccine Augmentation

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5